257 related articles for article (PubMed ID: 35363817)
1. Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy.
Burdette DL; Lazerwith S; Yang J; Chan HLY; Delaney Iv WE; Fletcher SP; Cihlar T; Feierbach B
PLoS One; 2022; 17(4):e0262516. PubMed ID: 35363817
[TBL] [Abstract][Full Text] [Related]
2. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
[TBL] [Abstract][Full Text] [Related]
3. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
5. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
7. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed.
Lai CL; Wong DK; Wong GT; Seto WK; Fung J; Yuen MF
JHEP Rep; 2020 Jun; 2(3):100112. PubMed ID: 32462119
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis.
Yu S; Jianqin H; Wei W; Jianrong H; Yida Y; Jifang S; Liang Y; Zhi C; Hongyu J
Ann Hepatol; 2013; 12(3):364-72. PubMed ID: 23619252
[TBL] [Abstract][Full Text] [Related]
9. Nucleos(t)ide analogues altered quasispecies composition of hepatitis B virus (HBV)-resistant mutations in serum HBV DNA and serum HBV RNA.
Liao H; Zhang H; Shao J; Li X; Zheng WV; Li L; Yu G; Si L; Zhou T; Yao Z; Dai J; Xu D; Cheng G; Qu J; Liu Y; Chen J; Lu F
J Med Virol; 2023 Mar; 95(3):e28612. PubMed ID: 36840474
[TBL] [Abstract][Full Text] [Related]
10. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
11. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection.
Burdette D; Hyrina A; Song Z; Beran RK; Cheung T; Gilmore S; Kobayashi T; Li L; Liu Y; Niedziela-Majka A; Medley J; Mehra U; Morganelli P; Novikov N; Niu C; Tam D; Tang J; Wang J; Yue Q; Fletcher SP; Holdorf MM; Delaney WE; Feierbach B; Lazerwith S
Antimicrob Agents Chemother; 2023 Jan; 67(1):e0134822. PubMed ID: 36519892
[TBL] [Abstract][Full Text] [Related]
13. Update on hepatitis B virus infection.
You CR; Lee SW; Jang JW; Yoon SK
World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
[TBL] [Abstract][Full Text] [Related]
14. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
[TBL] [Abstract][Full Text] [Related]
15. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs.
Lu F; Wang J; Chen X; Xu D; Xia N
Front Med; 2017 Dec; 11(4):502-508. PubMed ID: 29170915
[TBL] [Abstract][Full Text] [Related]
16. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
[TBL] [Abstract][Full Text] [Related]
17. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
Carey I; Gersch J; Wang B; Moigboi C; Kuhns M; Cloherty G; Dusheiko G; Agarwal K
Hepatology; 2020 Jul; 72(1):42-57. PubMed ID: 31701544
[TBL] [Abstract][Full Text] [Related]
18. Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis.
Barnes E
J Clin Invest; 2018 Feb; 128(2):573-576. PubMed ID: 29309052
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B Virus Capsid Assembly Modulators, but Not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA Variants.
Lam AM; Ren S; Espiritu C; Kelly M; Lau V; Zheng L; Hartman GD; Flores OA; Klumpp K
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559265
[TBL] [Abstract][Full Text] [Related]
20. [Research progress on the effect of hepatitis B virus DNA integration on antiviral therapy].
Zhao J; Chen XY; Zheng SJ
Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):375-379. PubMed ID: 38733195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
